Roche: lower the cost of your breast cancer drug so public health services can afford it!
Text by Margaret Connolly
” Thirteen years ago, a five-year old boy told me all he wanted for Christmas was, “Just one thing, Auntie Margaret: Five minutes with my mummy.”
It broke my heart – his wonderful mummy, Helen Mulhearn, had suffered an awful death 16 months before due to late-diagnosed breast cancer. At that time there were not many drugs that could have helped her. Then four and a half years ago, I was found to have breast cancer too. I was lucky – I was diagnosed early, and with standard breast cancer suitable for a drug that cost just pennies, thank God.
The breast cancer drug trastuzumab emtansine (also known as Kadcyla) will not be made routinely available on the NHS following a failure to reach an agreement on price between the National Institute for Health and Care Excellence (NICE) and the drug’s manufacturer, Roche.